Echocardiographic assessment and N-terminal pro-brain natriuretic peptide in hypertensives with metabolic syndrome

• Published in: Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2017-03, Vol.26 (2), p.295-301
• Main Authors: Krzesiński, Paweł, Uziebło-Życzkowska, Beata, Gielerak, Grzegorz, Stańczyk, Adam, Piotrowicz, Katarzyna, Piechota, Wiesław, Smurzyński, Paweł, Skrobowski, Andrzej
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Blood Pressure; Echocardiography, Doppler - methods; Female; Heart Rate; Humans; Hypertension - blood; Hypertension - complications; Hypertension - physiopathology; Hypertrophy, Left Ventricular - blood; Hypertrophy, Left Ventricular - complications; Hypertrophy, Left Ventricular - physiopathology; Male; Metabolic Syndrome - complications; Middle Aged; Natriuretic Peptide, Brain - blood; Natriuretic Peptide, Brain - chemistry; Peptide Fragments - blood; Peptide Fragments - chemistry; Reproducibility of Results; ROC Curve; Ventricular Dysfunction, Left - blood; Ventricular Dysfunction, Left - complications; Ventricular Dysfunction, Left - physiopathology
• ISSN: 1899-5276
• DOI: 10.17219/acem/33554

N-terminal pro-brain natriuretic peptide (NT-proBNP) release is associated with left ventricular expansion and pressure overload. Elevation of serum levels of natriuretic peptides is observed in patients with impaired as well as preserved left ventricular systolic function. High NT-proBNP has been shown to be related not only to preload but also to increased afterload, especially blood pressure and arterial stiffness. The aim of the study was to evaluate the association of NT-proBNP and echocardiographic parameters in hypertensives with metabolic syndrome. The study group comprised 133 patients (99 men; mean age 45.9 ± 9.4 years) with at least a 3-month history of arterial hypertension (stages 1 and 2) and fulfilling the diagnostic criteria for metabolic syndrome. Following initial clinical assessment, which included NT-proBNP levels, they underwent two-dimensional echocardiography. Echocardiographic abnormalities were observed in 60 subjects (45.1%), including left ventricular diastolic dysfunction (LVDdf) in 41 (30.8%) and left ventricular hypertrophy (LVH) in 35 (26.3%). Higher NT-proBNP concentrations were observed in patients with LVH, especially in the presence of LVDdf. Further analysis demonstrated that NT-proBNP correlated negatively with septal E' (r = -0.38; p = 0.015) and heart rate (r = -0.42; p = 0.006) in patients with LVDdf, and positively with left ventricular end diastolic diameter (r = 0.46; p = 0.006) and left ventricular mass index (r = 0.49; p = 0.005) in subjects with LVH. However, the analysis of ROC curves revealed no NT-proBNP level of good sensitivity and specificity in diagnosing LVDdf/LVH (maximal area under the curve 0.571). Even a relatively low NT-proBNP concentration can be a useful marker of left ventricular hypertrophy and end-diastolic wall stretch. However, in the present study there was no NT-proBNP level of satisfactory predictive value to diagnose LV abnormalities.